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Abstract Rosette-forming glioneuronal tumor (RGNT)
of the fourth ventricle is a mixed glio-neuronal neoplasm
recently codified by the World Health Organization WHO
Classification of Central Nervous System (CNS) Tumors
(2007). To date, 43 cases have been described in the lit-
erature; most occurring in the fourth ventricle region. We
report the fourth case involving the pineal region in a
16-year-old female with signs of increased intracranial
pressure (ICP). A stereotactic biopsy of the mass was fol-
lowed by a debulking procedure. Both specimens revealed
classic RGNT histology. The patient had stable scans
7 months post-resection. The clinical, radiological and
histopathologic features of the previously described 43
cases are reviewed along with our illustrative case. Mean
age of patients was 30 ± 12.8 years with 1.9:1 female to
male ratio. The most common presenting signs related to
increased ICP and posterior fossa involvement, including:
headache (62.8%), ataxia (39.5%) and vomiting and vertigo
(both 16.3%). This tumor usually presents with cystic
changes (54.5%) with focal enhancement (60.9%) and
hydrocephalus (43.2%). Microcalcifications and satellite
lesions were common radiographic observations. All repor-
ted cases had the classic biphasic pattern. Rosenthal fibers
and eosinophilic granular bodies are each present in
approximately two thirds of cases. Ki-67 labeling index is
consistently low (mean (%): 1.8 ± 0.75 SD). The isocitrate
dehydrogenase 1 or 2 mutation found in low grade diffuse
gliomas is not identified in this RGNT case. Reported
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outcome is nearly uniformly excellent after complete or
subtotal resection. A solitary report of recurrence after
10 years and the limited experience with this entity suggest
that long term follow up is advisable.
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Introduction
Posterior fossa tumors showing neuronal and glial differ-
entiation, with or without a ganglion component, have been
described in recent years [1]. Rosette-forming glioneuronal
tumor (RGNT) of the fourth ventricle (WHO grade I), a
rare slow growing tumor affecting mainly the young,
characterized by distinct neurocytic rosettes or perivascular
pseudorosettes and an astrocytic component, is one of the
rare benign mixed neuronal-glial neoplasms added in the
most recent edition of WHO Classification of Central
Nervous System (CNS) Tumors (2007) [2]. It was first
described as a dysembryoplastic neuroepithelial tumor
(DNET) of the cerebellum in 1995 [3] and was recognized
as a new entity in 2002, largely based on the reports of
Komori et al. who extensively described 11 cases [4–6].
RGNT was initially described as occurring solely in the
fourth ventricle and with possible extension into the sur-
rounding structures, including the cerebellar vermis, cere-
bello-pontine angle, midbrain and aqueduct of Sylvius
[4, 7, 8]. However, reports of origin from other sites in the
CNS, including the pineal region, have been documented
[4, 9]. Scheithauer et al. [10] described RGNT in the optic
chiasm in a 23-year-old Caucasian male with neurofibro-
matosis Type 1 (NF1). It was also reported in the cervical
spinal cord of a 44-year-old woman [11]. Recently, an
unusual widespread intraventricular dissemination of
RGNT was described in a 16-year-old Chinese girl with
stable outcome 7 months post-radiotherapy [12].
Consistently, reports show a high frequency of somatic
isocitrate dehydrogenase 1 (IDH1) and isoform IDH2 muta-
tion among oligodendrogliomas, astrocytomas and secondary
glioblastomas [13–21]. This mutation is exceedingly rare in
primary glioblastomas and pilocytic astrocytomas, and vir-
tually absent in meningiomas and ependymomas, suggesting a
different pathobiological mechanism or stem cell glial pre-
cursor. In a limited study, IDH1 mutation in gangliogliomas
was reported to be associated with poorer outcome, though
IDH1-positive gangliogliomas showed ‘‘atypical’’ features
pathologically [20]. Whether these IDH1 mutant cases are
diffuse gliomas with overrun neurons remains to be resolved.
As RGNT shares some morphologic features with low grade
gliomas and gangliogliomas, we carried out deoxyribonucleic
acid (DNA) sequencing of IDH1 [residue (R)132] and IDH2
(R172) mutation hotspots to assess whether they also occur in
this tumor.
Excluding this case, we identified 19 published papers
with 43 diagnosed RGNT cases to date. The prevalence of
some clinico-radiologic and histologic findings has not
been quantified; hence, it is also the objective of this report
to review the frequency of specific radiographic and his-
tologic findings, as well as analyze treatment and outcome
from previously-described cases to better elucidate the
nature of this rare neoplasm.
Case summary
A previously healthy 16-year old female presented for
chronic episodes of right-sided headaches and vomiting,
relieved with rest alone. On physical examination, her pupils
were noted to be sluggishly reactive to light and bilateral
papilledema was noted. Noncontrast computed tomographic
study of the head revealed a mass centered in the pineal gland
region with punctate calcification, extending into the pos-
terior aspect of the third ventricle. There was marked asso-
ciated obstructive hydrocephalus due to mass effect and
compression of the cerebral aqueduct. A subsequent cranial
magnetic resonance imaging (MRI) with gadolinium further
defined a heterogeneous, non- enhancing 3.8 cm 9 3.6
cm 9 3 cm mass in the pineal region, encroaching into the
posterior third ventricle (Fig. 1). MRI of the spine showed no
metastatic disease. A biopsy of the tumor was performed via
endoscopic third ventriculostomy. Tumor markers, includ-
ing beta-human chorionic gonadotropin, and alpha-fetopro-
tein were not significantly elevated in both the blood and
cerebrospinal fluid (CSF). The pathologic diagnosis was
RGNT. The patient was referred for tumor debulking
8 weeks post-biopsy as follow-up MRI revealed increasing
hydrocephalus. A suprasellar, infratentorial approach was
undertaken and subtotal resection was achieved. Post-oper-
atively, the patient showed significant improvement with no
reported complications. Follow-up imaging 2 months post-
resection revealed a residual mass in the pineal gland region
with stable hydrocephalus. Of note, the patient has stable
neurologic status and continues to see a pediatric endocri-
nologist for primary amenorrhea, which may be related to the
chronic hydrocephalus.
The review of RGNT cases was carried out through
searches in the literature using PubMed queries (up to and
including January 2010) for original articles (including
reviews) using a combination of the terms rosette forming
glioneuronal tumor and RGNT. The cited references of the
sources were also searched. The search yielded 30 papers
reporting a total of 43 RGNT cases. The pertinent clinical,
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radiographic and histological data are presented in tables
and further elucidated in the discussion.
Materials and methods
Histology and immunohistochemistry
Samples were fixed in 10% neutral formalin and paraffin-
embedded sections were stained with hematoxylin and eosin
for routine light microscopy. Immunohistochemical examina-
tions on 5-micron thick sections were performed on both speci-
mens using BenchMark XT (BMX), utilizing standard avidin–
biotin-peroxidase complex technique and diaminobenzidine as
chromogen with the following antibodies: glial fibrillary acidic
protein (GFAP) (1:200, GF2 clone, monoclonal, DAKO),
synaptophysin (Prediluted, 1:100, Ventana), neurofilament
(NF) (pre-diluted, 2F11, monoclonal, DAKO), and Ki-67
(1:100, clone MIB-1, monoclonal, DAKO).
IDH1/2 mutation analysis
DNA extraction
DNA was extracted from the patient’s resection specimen
(FFPE) using the Recoverall Kit (Applied Biosystems/Ambion,
Foster City, CA) according to manufacturer’s directions.
Polymerase Chain Reaction (PCR) amplification
PCR reactions for IDH1 and 2 amplification employed
similar methods published elsewhere [15, 18, 19]. An
IDH1 fragment of 237 bp in length spanning the sequence
including codon 132 (exon 4) was amplified using forward
5´GCGTCAAATGTGCCACTATC3´and reverse 5´-5´GCAA
AATCACATTATTGCCAAC3´ primers. An IDH2 frag-
ment of 265 bp in length of IDH2 spanning codon 172
(exon 4) was amplified using forward 5´CTCACAGAGTTC
AAGCTGAAGAAG3´ and reverse 5´CTGTGGCCTTGTAC
TGCAGAG3´ primers. PCR reactions were performed in
30 ll volume, including 20 ng of genomic DNA, 10 pmol
of each forward and reverse primer above, 19 PCR buffer,
0.3 mM dNTP, 1.5 mM MgCl2 and 0.5 unit of Platinum
Taq (Invitrogen, Carlsbad, CA). PCR conditions were:
94C for 1 min and 30 s; 5 cycles of 94C for 20 s, 65C
for 20 s, 72C for 20 s; 5 cycles of 94C for 20 s, 60C for
20 s, 72C for 20 s; 5 cycles of 94C for 20 s, 55C for
20 s, 72C for 20 s; and 30 cycles of 94C for 20 s, 50C
for 20 s, 72C for 20 s, followed by 72C for 10 min. 6 ll
of PCR product was loaded on a 2% agarose gel and
visualized under UV light.
Sequencing detection
The PCR products were purified using DNA Clean &
Concentrator Kit (Zymo Research, Orange, CA). 10 ng of
purified PCR product was used for sequencing reaction with
total volume of 10 ll, containing 1.6 pmol of sequencing
primers (IDH1 5´GCGTCAAATGTGCCACTATC3´ and IDH2
5´CTCACAGAGTTCAAGCTGAAGAAG3´), 19 sequenc-
ing buffer, 1.5 ll of BigDye Terminator v1.1(Applied Bio-
systems, Foster City, CA). Sequencing conditions were: 96C
for 1 min, followed by 25 cycles of 96C for 10 s, 50C for 5 s
and 60C for 4 min. The sequencing reactions were purified
Fig. 1 Preoperative MRI findings. a T1-weighted sagittal MRI
shows a heterogenous predominantly isointense to slightly hypoin-
tense mass (arrow) centered in the pineal region and extending to the
posterior aspect of the third ventricle. There is extensive associated
mass effect, including upon the tectum, with effacement of the
cerebral aqueduct. There is enlargement of the lateral and third
ventricles due to obstructive hydrocephalus. Multiple hypointense
foci within the tumor may indicate cystic areas. There is no extension
of tumor to the fourth ventricle or cerebral aqueduct; b T1-weighted
axial MRI with gadolinium shows no enhancement within the tumor
J Neurooncol (2011) 102:477–484 479
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using Performa DTR Gel Filtration Cartridges (Edge Bio,
Gaithersburg, MD) and analyzed on a 3730 sequencer
(Applied Biosystems) maintained by the UCLA Sequencing
Core.
Results
Histology and immunohistochemistry
Histologic examination of both biopsy and resection spec-
imens revealed a biphasic, moderately cellular neoplasm
(Fig. 2). The lesion was composed of a synaptophysin
immunoreactive neurocytic component characterized by
monomorphic cells with round hyperchromatic nuclei and
scant cytoplasm forming rosettes and perivascular pseud-
orosettes, and an extensively GFAP positive piloid glial
area similar to that in previously described RGNTs [2–12,
22–29]. Synaptophysin immunoreactivity was also noted in
the eosinophilic cores of rosettes and perivascular rosettes
formed by bland neurocytes. In areas of the glial compo-
nent, tumor cells arranged in cords and packets with fre-
quent peri-cellular halos resembling an oligodendroglioma
were found. Focal microcalcifications were identified.
Rosenthal fibers, eosinophilic granular bodies (EGBs),
mitoses, necroses and vascular endothelial hyperplasia were
not identified. Ki67 immunostain revealed a low prolifera-
tion index estimated at approximately 1% or less. Chro-
mogranin stain was largely negative and did not reveal
neoplastic ganglion cells.
IDH1 and 2 mutation analyses
IDH analysis of this tumor showed wild type genetic
sequences in exon 4 of both IDH1 (R132) and IDH2
(R172) genes.
Fig. 2 Histologic features:
a Low power microscopy
reveals a biphasic tumor with
neurocytic (right) and astrocytic
(left) components, H&E, 9200;
b Well-formed perivascular
rosettes and true rosettes (inset),
H&E, 91,000; c Strong
synaptophysin staining is noted
among neurocytes and
neurocytic cores, 9400; d High
power view of the
synaptophysin-positive
neurocytic cores, 91,000;
e Glial fibrillary acidic protein
immunostain highlights the
piloid astrocytic component,
9200; and f Collections of
oligodendrocyte-like cells are
present, H&E, 9400
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Discussion
Epidemiology of this neoplasm is limited since there are
relatively few published cases. In our review (Fig. 3), this
tumor was found to more commonly afflict young adults
(mean: 30 ± 12.8 years ), with nearly a two-fold female
predominance (1.9:1 female to male ratio), which is similar
to earlier findings [4, 24, 29].
The clinico-radiologic characteristics in our patient are
similar to those previously described. However, this tumor
largely involves the pineal region, abuts the posterior third
ventricle and impinges on the cerebral aqueduct causing
hydrocephalus, which is a less common observation.
Table 1 summarizes the clinical findings from previously
published data. Our patient presented with headache and
vomiting which are still the most commonly reported
symptoms in the review (Table 2). Ataxia (39.5%), vertigo
(16.3%), cranial nerve palsies (13.2%) and visual com-
plaints (11.6%), are also commonly observed. Signs and
symptoms appear to be related to the common location of
this tumor (see Table 1) which is the fourth ventricle
(31.8%) and contiguous structures (25%), and are related to
posterior fossa involvement and early development of
obstructive hydrocephalus from CSF flow interruption in
the fourth ventricle. Li et al. [25] reported intratumoral
hemorrhage in one patient leading to incidental diagnosis,
along with five other cases that did not have apparent
symptoms (14%).
Paramount concern among studies of ‘‘new’’ tumor enti-
ties is in regard to their natural history. This tumor appears to
have a variable growth pattern. Available data in 32 cases
(Table 1) show an extremely large gap in the reported
duration of symptoms, ranging from a few hours to 15 years
from the first report of neurologic disturbance (mean dura-
tion: 27.2 ± 44.6 months). One patient [7] presented
acutely in the emergency room secondary to intratumoral
bleeding, which led to sudden obstructive hydrocephalus. A
plausible explanation is that this tumor might have an
extremely indolent growth that patients do not recognize or
report symptoms, except in cases of inherent tumoral com-
plications (e.g. infarction, hemorrhage). The brain MRIs
show most consistently solid-cystic changes (54.5%) that are
iso/hypointense on T1-weighted images and hyperintense on
T2-weighted images and with high probability of enhance-
ment (whether ring-enhancement or heterogenous pattern,
65.9%; Table 1). Average size was 30.3 ± 16.8 mm in the
29 cases with available information. Eleven patients (25%)
showed calcifications while satellite lesions were noted in
Fig. 3 Age distribution of rosette-forming glioneuronal tumor cases
showing predominantly younger age group (11–40 age bracket). The
mean age at presentation is 30.3 ± 12.8 years with 1.9:1 female to
male ratio
Table 1 Summary of clinical and radiological features of rosette-
forming glioneuronal tumor cases
Patient demographics
Age in years, mean (SD) 30.3 (±12.8)
Gender, n (%)
Male 15/44 (39.5)
Female 29/44 (60.5)
Duration in months, mean (SD) 27.2 (±44.8)
Treatment, n (%)
GTR 25/44 (56.8)
STR 15/44 (34.1)
Biopsy 5/44 (11.4)
Radiotherapy 2/44 (4.5)
Post-op morbidity, n (%)
Yes 13/35 (37.1)
Noa 23/35 (65.7)
Follow-up in months, mean (SD) 30.2 (±35.7)
Outcome, n (%)
Stable 29/35 (94.3)
Death 1/35 (2.9)
Recurrence 1/35 (2.9)
Radiologic features
Location, n (%)
Fourth ventricle? 25/44 (56.8)
Cerebellum 10/44 (22.7)
Pineal 4/44 (9.1)
Others 5/44 (11.4)
Size in mm, mean (SD) 30.3 (±16.8)
Findings, n (%)
Enhancement 29/44 (65.9)
Cyst 24/44 (52.5)
Hydrocephalus 19/44 (43.2)
Calcification 11/44 (25)
Satellite lesion 7/44 (15.9)
SD standard deviation, NA data not available, GTR gross total
resection, SRT subtotal resection. Fourth ventricle? refers to tumor
originating from or centered in the fourth ventricle with involvement
of the contiguous structures
a Transient symptoms were included
J Neurooncol (2011) 102:477–484 481
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seven patients. Multiple lesions were extremely rare
occurrences.
RGNT is a newly recognized CNS tumor having biphasic
histologic characteristics [1, 30, 31]. The key features
[2], described in virtually all the reports, include: (i) a
neurocytic component composed of neurocytes forming
rosettes (resembling Homer-Wright rosettes) around a syn-
aptophysin-positive eosinophilic core and/or perivascular
pseudorosettes that are arranged in arrays towards a vessel
and (ii) an astrocytic component that is frequently described
as closely resembling that of a pilocytic astrocytoma. A
microcystic, myxoid matrix may be found in these neuro-
cytic structures, while oligodendroglia-like cells (OLCs)
may be seen in areas of the glial component. It has been
reported that these OLCs have strong synaptophysin
and Olig2 reactivity; however, they do not show 1p/19q
co-deletion [12]. Olig2, a transcription factor that controls
development and differentiation of oligodendrocytes, is
known to have variable expression in oligodendrocytes,
oligodendrogliomas, neuroepithelial tumors and other glio-
neuronal tumors [32–34]. In our review, Rosenthal fibers and
EGBs are each present in over 60% of cases. Nearly 1/2 of
cases have hyalinized blood vessels and myxoid stroma. In
1/3 of cases microcalcifications are noted (Table 3). ‘‘Dys-
morphic’’ ganglion cells are reported in five cases [4, 5].
‘‘Floating’’ Purkinje cells are specified in three cases [3, 29].
Whether the reported ‘‘dysmorphic’’ ganglion cells are also
‘‘floating’’ Purkinje cells remain to be clarified. Mitoses and
necrosis are generally absent. No ganglion cells were iden-
tified in our illustrative case. Neither the neurocytic nor the
astrocytic cellular component shows atypia.
The immunohistochemical profile in our case is compat-
ible with the previously published cases. Consistently
described is immunoreactivity for synaptophysin in the
neurocytic rosettes and perivascular pseudorosettes. Micro-
tubule associated protein 2 (MAP2) and neuron specific
enolase have also been reported to be expressed in the
neurocytic cell processes. GFAP and S-100 immunoreac-
tivity are variably present in the glial component, but are
absent in the neurocytic component. Ki-67 labelling index is
generally low, similar to the observation in our case (\1%).
Review of cases with available information shows a mean
Ki-67 index of 1.8 ± 0.75 (SD) (range: 0–3.8%).
RGNTs have been suggested to arise from cells of the
subependymal plate (periventricular germinal matrix) [4]
which have also been suggested as the site of origin of
DNETs of the cerebellum [1]. Whether this finding reflects
normal or aberrant developmental placement of precursor
or stem cells is uncertain. Increasing numbers of RGNTs
have been recognized in locations other than the fourth
ventricle. The alternate possibility of histologically similar
tumors with underlying genetic differences is not excluded.
Genetics of RGNT
Genetic abnormalities have not been well characterized in
RGNT though they have been found in other glioneuronal
tumors [35–38]. Due to very limited sample tissue avail-
ability in this case and given that chromosomes 1p/19q and
Olig2 gene have been previously studied, we chose only to
evaluate for IDH1 and 2 mutations.
IDH1 is a gene encoding cytosolic NADP ? -dependent
isocitrate dehydrogenase, an enzyme that catalyzes oxida-
tive decarboxylation of isocitrate to alpha-ketoglutarate. A
hotspot mutation is located at position 395 (R132). R172 in
exon 4 of IDH2 has the analogous function of R132 of
IDH1 and is similarly a mutational hotspot in the gene. It is
also suggested that IDH mutation is an early marker for
tumorigenesis of diffuse gliomas as it tends to occur earlier
than mutation of other genes including TP53, PTEN, and
EGFR [14, 15], but is non-existent or rare in other types of
brain tumors including gangliogliomas.
Table 2 Frequency of signs and symptoms observed in rosette-
forming glioneuronal tumor cases
Signs and symptoms Frequency (%)
Headache 27 (62.8)
Ataxia 17 (39.5)
Vertigo 7 (16.3)
Nausea/vomiting 7 (16.3)
Cranial nerve palsy 6 (14.0)
Incidental 6 (14.6)
Visual complaints 5 (11.6)
Motor sensory 4 (9.3)
Dysarthria 3 (7.0)
Seizure 1 (2.3)
Nystagmus 1 (2.3)
Hyperacussis 1 (2.3)
Table 3 Additional histologic features seen in rosette-forming
glioneuronal tumor cases
Pathologic finding Frequency (%)
Rosenthal fibers 29 (65.9)
Eosinophilic granular bodies 24 (64.5)
Myxoid stroma 21 (47.7)
Hyalinized vessels 19 (43.2)
Microcalcification 13 (29.5)
Neurons 9 (20.4)
Hemorrhage 5 (11.4)
Hemosiderin 4 (9.1)
Vascular endothelial hyperplasia 4 (9.1)
482 J Neurooncol (2011) 102:477–484
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To date, genetic studies performed on RGNT is limited
to evaluation for 1p19q loss [12] and neurofibromatosis
type 1 (NF1) gene deletion in chromosome 17 [10] by
fluorescent in situ hybridization; both of which were intact
in this low grade neoplasm. Our finding of wild type IDH1
and IDH2 genotypes in RGNT are consistent with prior
observations that mutations of those genes are relatively
specific for diffuse gliomas. Nevertheless, more work is
required to establish whether this finding is typical of
RGNT in general or pertinent to pineal RGNTs only.
Treatment and prognosis
The benign nature of this tumor has been repeatedly docu-
mented in most published studies. Despite a sizable number
of cases (43 documented), gross total or subtotal resection
(56.8% and 34% of cases respectively) appears to be
effective in treating this tumor, with excellent outcome and
with relatively little post-operative morbidity (Table 1).
Even patients who underwent biopsy alone remained stable
with 1–2 year follow up [8]. The majority of the cases did
well post-operatively, with over a half of the cases (51.4%)
having an unremarkable course or transient symptoms
(14.3%). Documented post-operative morbidities include:
ataxia (20%), cranial nerve palsy (17.1%) and others—
including isolated cases of dysmetria, dysphagia, mutism,
aggravation of presenting symptoms, and amenorrhea
(in our case, which was likely a complication of chronic
hydrocephalus). One patient who presented with dissemi-
nated intraventricular RGNT [12] was stable after radio-
therapy (46 Gy). One patient [4], after subtotal resection and
radiotherapy (5,500 cGy), died after 4 years, shortly after
developing progressive brainstem symptoms and a ring
enhancing lesion near the operative site. However, no
autopsy was performed and the lesion was attributed to
brainstem ‘‘radionecrosis’’. Only one case out of 35 (2.9%)
with follow up recurred and did so after 10 years (mean
follow-up (months): 30.3 ± 35.6) —see Table 1. Apart
from post-surgical changes, the recurrence showed the
typical RGNT histology. The value of treatment with radi-
ation of RGNT is unclear owing to the scarcity of treated
cases.
Conclusion
RGNT of the fourth ventricle is a distinct tumor entity that
also arises in other locations of the CNS. Whether the
tumor should be renamed will likely be a source of debate.
The presence of Rosenthal fibers and EGBs in a piloid
neoplasm involving the fourth ventricle or pineal region
should prompt consideration of RGNT and a search for the
typical neurocytic areas. We identify wildtype IDH1 and
IDH2 genes but additional cases would be helpful to con-
firm this not unexpected genotype in RGNT. It should
certainly be considered in the radiological differential
diagnosis of solid-cystic tumors of the posterior fossa
showing variable enhancement, with or without calcifica-
tion. While the course is nearly always benign, the rare
case of recurrence suggests that long-term follow up may
be desirable.
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